Introduction {#s1}
============

Dystonias (Dys), which manifest either as an isolated abnormal motor phenomenon or in combination with other motor and nonmotor signs of more complex neuropsychiatric syndromes, represent a relatively frequent movement disorder.[@b01],[@b02] Dys, in fact, represent the third most frequent movement disorder after essential tremor (ET) and Parkinson\'s disease (PD).[@b03]

A number of efforts have led to various classification systems of Dys,[@b04]--[@b08] attempts to characterize their biological bases,[@b09]--[@b13] and multiple proposals of clinical guidelines for their treatment.[@b14]--[@b16] However, although important progress has been achieved in understanding some of the neurological bases of Dys, especially in terms of molecular mechanisms[@b17] and genetic causes,[@b18] the distinct characteristic neuropathologic features of Dys remain poorly defined[@b19] with some very rare exceptions.[@b20],[@b21]

There have been few clinicopathologic correlation studies of postmortem brain tissues from Dys patients, with most analyses described in sporadic case-reports.[@b22]--[@b27] These neuropathologic studies have proven to be mostly inconclusive due to the clinical heterogeneity of Dys cases examined, the different classification systems used, and more importantly, difficulty in obtaining brains from clinically well-characterized Dys patients.[@b28] However, a few neuropathologic studies have begun to shed light on possible neuropathologic and morphometric aspects of specific types of Dys, such as DYT1-dystonia (DYT1),[@b29] cervical dystonia (CD)[@b30], and dopa-responsive dystonia (DRD).[@b31] Rostasy and colleagues assessed brains from five patients with DYT1 (GAG-deletions) and three Dys patients without GAG-deletions and reported larger and more compacted pigmented neurons in the substantia nigra (SN) of both types of Dys compared to control subjects (C).[@b29] In contrast, Göttle et al. described smaller SN neurons in Lesch-Nyhan disease.[@b32] In general, these lines of evidence support the hypothesis that the SN is indeed involved in Dys pathogenesis.[@b33]--[@b35]

The primary aim of this study was to investigate morphometric aspects of neuromelanin-containing (pigmented) neurons in the SN of Dys patients by performing rigorous neuropathologic quantitative analyses. We aimed to estimate nigral pigmented neuronal counts and cell body, nuclear, and nucleolar volumes using established quantification methods and the largest number of publicly available Dys autopsy brains to date.

We observed a significant decrease in the number of pigmented neurons in the SN of Dys brains versus C. This reduction was present in the SN of patients with both adulthood- and childhood-onset Dys. Interestingly, fewer pigmented neurons in the SN were not associated with significant changes in cellular, nuclear, or nucleolar volumes of the remaining pool of nigral pigmented neurons, or with other major neuropathologic and neurodegenerative signs. These findings might indicate that a reduction in SN pigmented neurons in Dys patients could be due to a neurodevelopmental defect rather than a neurodegenerative process.

A nigral pigmented neuronal reduction in the absence of cellular (cell body) and subcellular (nuclear/nucleolar) volumetric changes in the SN of Dys brains was confirmed by excluding other possible confounding or co-occurring nigral pathologies with immunohistochemistry protocols. In this study, the Dys and C groups did not differ in terms of mean age at death, further minimizing the influence of the important confounding factor of age.[@b36]

Methods {#s2}
=======

A total of 13 SN from patients (9 females and 4 males) with various Dys subtypes were available for this study. The mean age at death was 68.8±15.5 years (range: 44--95). These individuals had a history of childhood- or adulthood-onset Dys with focal, segmental, or generalized distribution. Dys cases did not show signs of any other major neurological, psychiatric, or medical disorders except for one patient with diagnosis of possible dementia with Lewy bodies (possDLB), and another with cardiovascular disease. Cases of DYT1, the most frequent genetic form of Dys, were excluded from this investigation to avoid performing measurements on neurons from the brains of patients with Dys attributable to specific genetic causes. With this exclusion, we aimed to obtain general but specific quantitative findings on non-DYT1 or idiopathic Dys only.

The 13 SN from Dys patients were compared to 13 SN from age-matched control subjects (C, 9 females and 4 males). The mean age at death was 64.3±13.8 years (range: 44--88 years). C did not show clinical or pathologic evidence of any major neurological, psychiatric, or medical disorders except for heart disease in some cases.

In addition to the standard microscopic neuropathological assessments, all SNs were immunohistochemically assessed for the presence of: *α*-synuclein-positive Lewy bodies (LB) and Lewy neurites (LN), hyperphosphorylated-tau neurofibrillary tangles (tau-NFT), hyperphosphorylated-tau threads (tau-th), ubiquitin (ubiq), intraneuronal cytoplasmic inclusions of phosphorylated-TAR-DNA binding protein-43 (pTDP-43), and extracellular deposits of insoluble 1--42 *β*-amyloid (diffuse-A*β* and A*β*-neuritic plaques). Subjects with neuropathologic findings indicative of any other neurodegenerative disorder or severe cerebrovascular disease were excluded from the study.

All Dys and C brains were collected after obtaining written consent from the next-of-kin or legal representative and after approval from each institution where the case was examined. Tissues were obtained from the University of Maryland Brain and Tissue Bank (UMBTB). The use of these tissues was approved by UMBTB and the local Institutional Research Board. Each hemibrain was fixed in 10% buffered formalin for at least 2 weeks and then grossly and microscopically examined in coronal sections for a general neuropathologic assessment at UMBTB.

Neuropathology and quantitative methods {#s2a}
---------------------------------------

Each hemi-SN block was randomly cut at different anatomical levels along the rostro-caudal anatomical axis of the structure. This anatomically random cutting minimized possible anatomical selection biases. We were unable to obtain the entire SN for each subject, but we were confident that at least three quarters of the entire structure was actually sampled for each case. This conclusion was based on our samples measurements (see below) in comparison to previous anatomical studies that assessed the entire length of SN.[@b37],[@b38]

Tissue cutting and procedures for morphometric-quantitative analyses {#s2b}
--------------------------------------------------------------------

The total length of each block of formalin-fixed SN received ranged from 8--10 mm. Tissues were processed at the Neuropathology Research labs at the Biomedical Research Institute of New Jersey (BRInj). Tissue blocks were processed with an automated tissue-processor (Tissue-Tek V.I.P. 1000 Vacuum Infiltration Processor, Ames Division, Miles Laboratories, Inc., Elkhart, IN, USA) using standard protocols. Tissue blocks were then embedded in paraffin, oriented with the rostral area facing the bottom of the paraffin mold, and serially cut along the rostro-caudal direction using a semi-automatic microtome (Leica RM2255, Leica Biosystems, Nussloch, Germany). Each block was cut for its entire length in series of 40 µm-thick consecutive sections, alternating to a series of 16 consecutive 10 µm-thick sections. These serial, consecutive, and alternating sectioning procedures guaranteed the constancy of the established sampling rate for this investigation (one every five 40 µm-thick sections) and simultaneously allowed the use of 10 µm-thick consecutive sections anatomically adjacent to the 40 µm-thick sections for further immunohistochemistry assessments and volumetric measurements.[@b39]

The mean length of the sampled SN did not differ between Dys and C brains (mean lengths of 9,392.31±1,518.99 µm and 10,015.38±1,573.2 µm, respectively). The total number of consecutive sections (including 40 µm- and 10 µm-thick sections) obtained for Dys and C were 792.9±129.3 and 845.4±132.3, respectively. No statistical differences in terms of total length of sampled tissue and number of sections obtained were present between the Dys and C groups. Means of 48.6±7.5 and 51.6±7.5 40 µm-thick consecutive sections were respectively obtained for Dys and C.

Each set of 40 µm-thick sections was stained with a 1.0% cresyl violet (CV) solution for neuronal counting.[@b40] Each set of 40 µm-thick sections was separately and randomly recoded by an investigator blinded to the clinical and pathologic diagnoses (M.G.E.). Quantitative measurements using well-established stereological probes (the Optical Fractionator and Nucleator, see below) were performed by a second investigator (D.I.). Slides codes were opened, and statistical analyses were performed only after all measurements were completed.

A single 10 µm-thick tissue section was randomly chosen, stained with hematoxylin and eosin (H&E), and microscopically inspected at low (2.5×) and high (20×) magnifications to assess for possible micro-ischemic vascular pathologies, microhemorrhages, tissue rarefaction, and other possible histologic abnormalities not visible on gross examination.

Procedures for SN neuropathologic quantitative measurements {#s2c}
-----------------------------------------------------------

Each section was stereoscopically inspected (2×) across the entire sectional area to localize SN anatomical borders. The pars compacta and pars reticulata were identified and marked as based on previous detailed anatomical descriptions.[@b41]

For neuronal counting, the following histologic criteria were applied:

1.  Use of 40 µm-thick sections;

2.  Inclusion of any neuron, of any size, containing neuromelanin pigment;

3.  Exclusion of nonneuronal cells containing neuromelanin pigment, such as macrophages.

For neuronal volumetric measurements, the following histologic criteria were applied:

1.  Use of 10 µm-thick sections;

2.  Individuation of a well-defined nonneuromelanin-covered nucleolus for each randomly sampled pigmented neuron;

3.  Establishing the nucleolus as the only point of reference for all volumetric measurements in each randomly sampled pigmented neuron.

Measurements were performed using the Stereo-Investigator system, Version 10.0 (MBF Bioscience, Williston, VT, USA), equipped with a digital camera (AxioCam MRm, and MRc, Zeiss, Oberkochen, Germany) and multiple objective head (2.5--100× oil-immersion). The sampling grid area was 500×500 µm, the counting frame was 40×40 µm, and the disector height was 25 µm with guard zones of ±2 µm. The total number of SN pigmented neurons was estimated using the Optical Fractionator probe.[@b42],[@b43]

Series of 10 µm-thick consecutive sections adjacent to each previously analyzed 40 µm-thick section were stained with CV to measure the cellular, nuclear, and nucleolar volumes of pigmented neurons. Volumetric measurements were performed using the Nucleator probe.[@b38] Pigmented neuron volumes were measured by placing six rays that automatically centered on the nucleolus and randomly intersecting the cell membrane (**[Figure 1A](#f01){ref-type="fig"}**). Pigmented neurons were measured if their nucleolus was inside the counting frame intersecting or touching the green inclusion line; they were excluded if their nucleolus intersected or touched the red exclusion line (**[Figure 1A](#f01){ref-type="fig"}, upper right quadrant**). This second-run of volumetric measurements on separate sets of 10 µm-thick consecutive sections was chosen to increase the number of available pigmented neurons showing a well-defined nucleolus, that is, the established point of spatial reference for volumetric measurements in this study. In fact, a consistent number of pigmented neurons that could be clearly counted on 40 µm-thick sections could not be volumetrically measured due to the presence of neuromelanin covering, partially or totally, the nucleolus (**[Figure 1B](#f01){ref-type="fig"}**).

![**Quantification of SN Pigmented Neurons.** The quadrants in the figure show how a randomly sampled pigmented neuron (first upper-right quadrant, 20× objective), and 6 randomly projected rays on that pigmented neuron intersect its cell body, nucleus, and nucleolus (respectively, upper-right, lower-left, and lower-right quadrant). A 100× oil immersion objective was used for all volumetric measurements and for each pigmented neuron. The green markers in each quadrant indicate the point of measurement from which the areas of the cell body, nucleus, and nucleolus were calculated. The colored square upper-right quadrant represents the "counting frame" used for the Optical Fractionator probe. The Stereo-investigator software automatically calculates the volumes of each single neuron computing various parameters such as the thickness of the tissue, the disector height, and guard zones. **[Figure 1B. Tissue thickness, cell counting, volumetric measurability of nigral pigmented neurons](#f01){ref-type="fig"}**. SNc from a C brain (case\#16), cut at different levels of thicknesses (40 µm and 10 µm), stained with CV, and inspected at two different magnifications (10× and 20× objectives). The green circles in the inferior parts of the figure indicate the number of pigmented neurons measurable when pigmented neurons were sampled using 40 µm-thick and 10 µm-thick tissue sections, respectively, with a 20× objective. Notably, the number of measurable pigmented neurons in SN cut at 10 µm of thickness (right of figure) is markedly higher due to the increased number of clear visible CV-stained nucleoli. The nucleolus was the established point of spatial reference on this study. All measurements were performed using a 100× oil-immersion, NA 1.30, neofluor ∞/0.17 objective. Abbreviations: C, Control; CV, Cresyl Violet; SN, Substantia Nigra; SNc, Pars Compacta of Substantia Nigra.](tre-05-301-6570-1-g001){#f01}

Immunohistochemistry {#s2d}
--------------------

Each Dys and C case underwent an extensive immunohistochemical assessment. For each case, we examined 16 10-µm thick sections adjacent to the median 40 µm-thick set of sections. The 10 µm-thick tissue sections were deparaffinized, hydrated, and treated to block endogenous peroxidase activity (3% hydrogen peroxide in water). They were then rinsed in buffer (Tris with 0.05% Triton-X), microwaved with antigen retrieval solution (sodium citrate, pH 6.0) for 10 minutes, and cooled. Protein block (1.5% horse serum) was applied for 30 minutes. The following antibodies were used: mouse anti-*β*-amyloid, 17--24 (dilution 1:500, 4G8; SIG-39220, Covance, Princeton, NJ, USA) with overnight incubation at 4°C (sections were pre-treated with 90% formic acid, 5 minutes); mouse anti-PHF-tau (dilution 1:500, MN1020; Thermo Fisher Scientific, Waltham, MA, USA); mouse anti-*α*-synuclein (dilution 1:500, Ab27766; Abcam, Cambridge, UK) rabbit anti-ubiq (dilution 1:250, ab7780, Abcam); rabbit anti phospho-TDP-43 (dilution 1:2,000, TIP-PTD-P02; Cosmo Bio Co. LTD, Carlsbad, CA, USA). With the exception of the anti-*β*-amyloid antibody, sections were incubated overnight at 4°C, rinsed with buffer, incubated with biotinylated horse anti-mouse or anti-rabbit secondary antibodies (30 minutes), Vector Kit reagents (Vector Labs, Inc., Burlingame, CA, USA), then with a 3, 3\'-diaminobenzidine substrate system (D3939; Sigma, St. Louis, MO, USA) for 5 minutes. Slides were counterstained with hematoxylin, dehydrated in xylene, and coverslipped.

Statistical analyses {#s2e}
--------------------

Statistical analyses for quantification and volumes were performed to compare Dys and C, adulthood-onset Dys and C, childhood-onset Dys and C, childhood-onset Dys and adulthood-onset Dys, and generalized and segmental/focal Dys. All comparisons were computed before and after excluding co-occurring pathology (LB, LN, tau-NFT, tau-th, ubiq, and pTDP43 inclusions, *β*-amyloid deposits). The childhood-onset Dys group included subjects with early adulthood-onset diagnoses and the only subject with posttraumatic Dys (Dys\#10, onset at age 12).

Neuronal counting results revealed a Gaussian distribution, and a *t*-test was initially performed to compare Dys and C and Dys and C without copathologies. Furthermore, we performed analyses of variance (ANOVAs) with Tukey\'s posthoc tests across all comparisons. The Tukey\'s test compares every mean with every other mean and takes into account multiple comparisons and adjusted *p*-values for each comparison. Statistical significance was established at *p*\<0.01 (adjusted for all five types of comparisons).

The preliminary analyses for the obtained neuronal volumetric measurements did not show a Gaussian curve, so nonparametric Mann-Whitney tests were performed across all comparisons for those measurements. Data refer to the values estimated for the bilateral SN. All computations were performed using GraphPad Prism software, version 5 (GraphPad Software, Inc., La Jolla, CA, USA).

Results {#s3}
=======

The demographic, medical, and genetic data for both the Dys and C groups are summarized in [Table 1](#t01){ref-type="table"}. [Table 1](#t01){ref-type="table"} shows diagnoses of Dys as received from UMBTB records, while [Table 2](#t02){ref-type="table"} classifies each Dys patient based on a review of supplemental medical records according to the newest Dys classification system.[@b04] This most recent classification system was not available for any of the subjects in this cohort at the time of their clinical diagnosis. [Table 2](#t02){ref-type="table"} also summarizes all available data in terms of age at onset, body distribution, temporal pattern, variability, associated features, occurrence of other neurological and systemic manifestations, and etiologies (i.e., following the Axis I and II of the newer classification).[@b04] In terms of temporal patterns, 3 out of 13 Dys cases were classified as adulthood onset, 3 as early adulthood onset, 6 as childhood onset, and 1 case of childhood-onset posttraumatic Dys. For body distribution, 6 out of 13 Dys cases were classified as generalized, 6 as segmental/focal, and 1 segmental/focal posttraumatic Dys.

Table 1Demographic, Diagnostic, Genetic, and Medical Data.Subject\#/UMBTB CodeAge at DeathSexDiagnosis (As Received)GeneticsOther Relevant Medical Data**1 (Dys)/1458**62MDystoniaNeg for GAG del in DYT1None**2 (Dys)/1484**81FDystonia (started as blepharospasm)Not tested for DYT1 mutationsNone**3 (Dys)/1850**50FDystonia (started at 42 years old: adulthood onset, focal and segmental)Not tested for DYT1 mutationsMother with PD, multiple drugs**4 (Dys)/4897**49FDystonia (generalized)Neg for GAG del in DYT1None**5 (Dys)/4880**44FDystonia (generalized dystonia with involvement of trunk, limbs, neck, and flexion contractures in the right leg; severe episodes of jerking \[head back and forth\] with generalized body contortions; possible seizures generalized)Neg for GAG del in DYT1Brain aneurysm, intracerebral hemorrhage, multiple drugs**6 (Dys)/5145**84FDystonia (cervical dystonia for \>4 decades, head begun to turn 43 years before death with pain 20 years later, mouth involvement 22 years later)Not tested for DYT1 mutationsFather with tremor (unspecified)**7 (Dys)/5414**95FDystonia (tremor since the 6th grade, myoclonic jerks and terminal intentional tremor, marked paraspinal muscles spasms with lordosis, spastic dysphonia)Not tested for DYT1 mutationsNone**8 (Dys)/5421**81FDystoniaNot tested for DYT1 mutationsNone**9 (Dys)/1457**72MDystoniaNeg for GAG del in DYT1None**10 (Dys)/1353**78MDystonia (severe bike-automobile accident at 12 years old caused a fractured skull, tremor and posttraumatic dystonia followed)Neg for GAG del in DYT1None**11 (Dys)/4635**76MDystonia (generalized in combination with cervical myelopathy, initial cervical dystonia at 27 years old)Neg for GAG del in DYT1History of familial dystonia symptoms (father and sister), possDLB**12 (Dys)/1481**64FDystoniaNeg for GAG del in DYT1Diabetes, congestive heart failure, angina, angioplasty, daughter with dystonia**13 (Dys)/1554**59FDystoniaNeg for GAG del in DYT1Small cell carcinoma, pneumonia, history of dystonia preceding lung carcinoma**14 (C)/4263**61MControlNot testedIschemic cardiomyopathy, heart transplant, left ventricular dysfunction, depression, chronic renal failure, diabetes mellitus**15 (C)/4921**73FControlNot testedGallbladder dysfunction, high blood pressure**16 (C)/5357**51FControlNot testedDrug overdose, suicidal attempt**17 (C)/4788**48FControlNot testedMultiple injuries resulting from a motorcycle accident**18 (C)/4228**44FControlNot testedNone**19 (C)/5219**76FControlNot testedNone**20 (C)/M3642M**88FControlNot testedCongestive heart disease**21 (C)/5274**64FControlNot testedHypertension, heart disease, skin cancer**22 (C)/1818**76MControlNot testedNone**23 (C)/5171**79MControlNot testedCOPD**24 (C)/M3903M**71MControlNot testedCoronary artery disease, coronary angioplasty (twice), COPD**25 (C)/1503**53FControlNot testedKnee surgery after falling**26 (C)/1379**53FControlNot testedHigh blood pressure, asthma[^1] Table 2Dys Patients Classified Following the Newer Classification System of Dystonia. The table shows the specific diagnosis of Dys for each patient in study based on the Axis I (clinical features) and Axis II (etiologies) of the newer Dys classification system.[@b04]Subject\#Diagnosis (As Received)Dystonia Diagnosis based on the Newer ClassificationDystonia Diagnosis based on the Newer Classification**Axis IAxis II(Clinical Features)(Etiology)1 (Dys)**DystoniaAge at onset: not reported (probably childhood-onset as for medical history)Nervous system pathology: no evidence of degeneration or structural lesionsBody distribution: not reported (probably generalized as for medical history)Inherited: possibleTemporal pattern: not reportedAcquired: noVariability: not reportedIdiopathic: yesAssociated features: unknown/not clinically significantOccurrence of other neurological/systemic manifestations: unknown/not clinically significant**2 (Dys)**Dystonia (started as blepharospasm in 1983, 22 years of dystonia history until death)Age at onset: late adulthoodNervous system pathology: no evidence of degeneration or structural lesionsBody distribution: initially focal, then segmental (oromandibular dystonia with jaw closure and lip pursing, facial grimacing)Inherited: no (aunt, mother\'s sister, with resting tremor)Temporal pattern: staticAcquired: noVariability: diurnalIdiopathic: yesAssociated features: headache (with temporal and orbital pain)Occurrence of other neurological/systemic manifestations: tardive dyskinesia secondary to adverse effects to metoclopramide, moderate bradykinesia, rigidity, and rest tremor; possible side effects of various drugs used for the treatment of the blepharospasm**3 (Dys)**Dystonia (started at 42 years old: adulthood onset, focal and segmental)Age at onset: late adulthoodNervous system pathology: evidence of degeneration (SN)Body distribution: focal, segmental (face, neck, shoulders), dysphagiaInherited: no (mother with PD)Temporal pattern: staticAcquired: noVariability: diurnalIdiopathic: yesAssociated features: unknown/not clinically significantOccurrence of other neurological/systemic manifestations: unknown/not clinically significant**4 (Dys)**Dystonia (generalized)Age at onset: childhoodNervous system pathology: no evidence of degeneration or structural lesionBody distribution: generalized (with leg involvement)Inherited: noTemporal pattern: progressiveAcquired: noVariability: diurnalIdiopathic: yesAssociated features: headache (not clinically significant)Occurrence of other neurological/systemic manifestations: unknown/not clinically significant**5 (Dys)**Dystonia (generalized)Age at onset: childhoodNervous system pathology: cerebellar cortical degenerationBody distribution: multifocal neck, trunk, limbs), segmental (leg involvement)Inherited: noTemporal pattern: progressiveAcquired: noVariability: paroxysmalIdiopathic: yesAssociated features: pain, headacheOccurrence of other neurological/systemic manifestations: frontal lobe intracerebral hemorrhage (after many years of generalized dystonia)**6 (Dys)**Dystonia (cervical dystonia for \>4 decades)Age at onset: early adulthoodNervous system pathology: no evidence of degeneration or structural lesionBody distribution: segmental (started as cervical dystonia, then mouth and lingual involvement)Inherited: unknown (father with head tremor)Temporal pattern: progressive (mount involvement, paraspinal muscles spasm, spastic dysphonia)Acquired: noVariability: diurnalIdiopathic: yesAssociated features: facial painOccurrence of other neurological/systemic manifestations: resting hand tremor (later, after many years cervical dystonia appearance)**7 (Dys)**DystoniaAge at onset: childhoodNervous system pathology: no evidence of degeneration or structural lesionBody distribution: segmental (truncal, paraspinal spams with lordosis)Inherited: noTemporal pattern: diurnalAcquired: noVariability: diurnalIdiopathic: yesAssociated features: spastic dysphonia, tremor started in 6th gradeOccurrence of other neurological/systemic manifestations: unknown**8 (Dys)**DystoniaAge at onset: late adulthoodNervous system pathology: evidence of degeneration (SN), LB pathologyBody distribution: segmental (started as blepharospasm then spasmodic dysphonia; lip pursing, grimacing, and jaw opening)Inherited: noTemporal pattern: staticAcquired: noVariability: diurnal (getting worse with action); not action-specific but with associatedIdiopathic: yesfeatures of late-onset tardive dyskinesia (oromandibular, pharyngeal, and facial dystonia) due to possible side effects of neuroleptic drugs (perphenazine/amitriptyline)Occurrence of other neurological/systemic manifestations: unknown/not clinically significant**9 (Dys)**DystoniaAge at onset: childhood (probably)Nervous system pathology: cerebellar atrophy (moderate)Body distribution: generalizedInherited: noTemporal pattern: progressive (probably)Acquired: noVariability: diurnalIdiopathic: yesAssociated features: unknown/not clinically significantOccurrence of other neurological/systemic manifestations: unknown/not clinically significant**10 (Dys)**Dystonia (posttraumatic)Age at onset: childhoodNervous system pathology: cerebellar atrophy, LBs in the SN and LCBody distribution: focal (right hand)Inherited: noTemporal pattern: staticAcquired: yes, (posttraumatic)Variability: persistentIdiopathic: noAssociated features: tremor (right hand)Occurrence of other neurological/systemic manifestations: unknown/not clinically significant**11 (Dys)**Dystonia (generalized in combination with cervical myelopathy; initial cervical dystonia at 27 years old)Age at onset: early adulthoodNervous system pathology: diffuse LB pathology (brainstem, cortex), cerebellar heterotaxia (white matter)Body distribution: generalizedInherited: possible (reported familiarity for movement disorders)Temporal pattern: progressive (started as cervical dystonia/torticollis then progressed with arms and legs)Acquired: noVariability: diurnalIdiopathic: yesAssociated features: marked diffuse tremorOccurrence of other neurological/systemic manifestations: possible dementia**12 (Dys)**DystoniaAge at onset: early adulthoodNervous system pathology: no evidence of degeneration or structural lesionBody distribution: generalizedInherited: possible (daughter with dystonia)Temporal pattern: progressiveAcquired: noVariability: diurnalIdiopathic: yesAssociated features: unknown/not clinically significantOccurrence of other neurological/systemic manifestations: mastectomy for breast cancer**13 (Dys)**DystoniaAge at onset: childhood (probably)Nervous system pathology: no evidence of degeneration or structural lesion (metastatic cells in cerebrum, cerebellum, brainstem)Body distribution: generalizedInherited: noTemporal pattern: progressiveAcquired: noVariability: diurnalIdiopathic: yesAssociated features: unknown/not clinically significantOccurrence of other neurological/systemic manifestations: lung cancer[^2]

All main neuropathologic data, postmortem delay (PMD, time between death and autopsy) values, and causes of death are shown in [Table 3](#t03){ref-type="table"}. The mean PMD was 11.7±6.4 hours, with no significant differences between the Dys (13±6.7 hours) and C (10.4±6.0 hours) groups. The majority of Dys and C did not show signs of major recent or remote ischemic, hemorrhagic lesions, metastatic infiltration, or arteriovenous or congenital malformations. The exception was case\#5 (Dys who showed microhemorrhages, probably due to the prolonged periagonal status and history of remote hemorrhage from an aneurysmatic rupture. Intima thickening was observed in most of the arteries and arterioles in case \#3, \#12, \#13, and \#23, which was compatible with arteriosclerotic disease (see [Table 4](#t04){ref-type="table"}).

###### Causes of Death, Autopsy Data, and Main Neuropathologic Findings.

  Subjects\#     BW (Grams)   PMD (Hours)   Cause of Death                                          Main Neuropathologic Findings
  -------------- ------------ ------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1 (Dys)**    1,455        12            Natural                                                 No significant neuropathologic findings
  **2 (Dys)**    N/A          16            Natural                                                 Remote infarct in right parieto-occipital region; moderate cerebral artery atherosclerosis
  **3 (Dys)**    N/A          3             Brain ischemic injury                                   Acute hypoxic-ischemic encephalopathy, idiopathic SN degeneration
  **4 (Dys)**    N/A          16            Complications of the disorder (multiple falls)          No significant neuropathologic findings
  **5 (Dys)**    N/A          20            Complications of the disorder                           Encephalomalacia involving frontal lobes with subarachnoid hematoma due to ruptured berry aneurysm and surgical clip placement, cerebellar cortical degeneration
  **6 (Dys)**    N/A          20            Complications of the disorder                           Generalized mild atrophy, arteriosclerotic cerebrovascular disease
  **7 (Dys)**    N/A          16            Complications of the disorder                           Neocortical gyral atrophy, arteriosclerosis with leukomalacia
  **8 (Dys)**    N/A          8             Complications of the disorder                           Diffuse brain atrophy, arteriosclerotic cerebrovascular disease, SN degeneration with LBs in the SN and limbic cortex, AD-type lesions (amyloid neuritic plaques and neurofibrillary tangles) in the hippocampus
  **9 (Dys)**    N/A          12            Natural                                                 Microscopic remote infarct in the left caudate, moderate cerebellar atrophy
  **10 (Dys)**   N/A          5             Septic shock, metabolic acidosis, respiratory failure   Mild cerebral hemispheric atrophy, rare LBs in the SN and LC, mild cerebellar atrophy
  **11 (Dys)**   N/A          9             Complications of the disorder                           Amyloid neuritic plaques in the cortex; diffuse LBs in the SN, limbic structures, and cortical regions; incidental cerebellar white matter heterotopia
  **12 (Dys)**   N/A          26            Natural                                                 No significant neuropathologic findings
  **13 (Dys)**   N/A          6             Lung cancer                                             Metastatic poorly differentiated carcinoma in the cerebrum, cerebellum, and brainstem
  **14 (C)**     1,309        6             Cardiac arrest                                          Small cystic infarcts in the left parieto-occipital and frontal lobes
  **15 (C)**     N/A          13            Peritonitis                                             No significant neuropathologic findings
  **16 (C)**     N/A          8             Atherosclerosis-Cardiovascular disease                  No significant neuropathologic findings
  **17 (C)**     N/A          17            Multiple traumatic injuries                             No significant neuropathologic findings
  **18 (C)**     1,260        16            Coronary artery atherosclerosis and thrombosis          Acute hypoxic-ischemic encephalopathy in hippocampus
  **19 (C)**     N/A          3             Complications of cancer                                 No significant neuropathologic findings
  **20 (C)**     N/A          8             Congestive heart failure                                No significant neuropathologic findings
  **21 (C)**     N/A          20            Acute cerebrovascular disease                           No significant neuropathologic findings
  **22 (C)**     N/A          3             Acute cerebrovascular disease                           Mild to moderate atheromatosis of the circle of Willis, arteriosclerosis of the middle- and small-sized intraparenchymal arteries, microinfarct in the right Sommer\'s sector (cornu ammonis 1 of the hippocampus)
  **23 (C)**     N/A          5             COPD, peripheral vascular disease                       No significant neuropathologic findings
  **24 (C)**     N/A          16            Cardiac arrest                                          Brain edema
  **25 (C)**     N/A          5             Pulmonary thromboembolism                               No significant neuropathologic findings
  **26 (C)**     N/A          15            Respiratory distress                                    No significant neuropathologic findings

Abbreviations: AD, Alzheimer\'s Disease; BW, Brain Weight; C, Control; COPD, Chronic Obstructive Pulmonary Disease; Dys, Dystonia; LB, Lewy Body; LC, Locus Coeruleus; N/A, Not Applicable; PMD, Postmortem Delay; SN, Substantia Nigra.

###### H&E and Immunohistochemistry Assessment of other SN Pathologies. The table shows the types and frequencies of co-occurring brain pathologies in the SN of Dys and C subjects. Co-occurring brain pathologies were assessed by specific immunohistochemistry protocols for the following antigens: 1--42 *β*-amyloid, hyperphosphorylated-tau, *α*-synuclein, ubiq, and phosphorylated-TDP43. The lesions considered were 1--42 *β*-amyloid diffuse and neuritic plaques, hyperphosphorylated-tau positive NFTs, tau threads, and ubiq- and phosphorylated-TDP43-positive intraneuronal cytoplasmic inclusions.

  Case\#         1--42 *β*-amyloid   Hyperphosphorylated-tau         *α*-synuclein   Ubiq-cytopl. incl./MB   Phosphorylated-TDP43   H&E
  -------------- ------------------- ------------------------------- --------------- ----------------------- ---------------------- --------------------
  **1 (Dys)**    Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **2 (Dys)**    Neg                 Neg                             Neg             Neg/Pos                 Neg                    Normal
  **3 (Dys)**    Neg                 Neg                             Neg             Neg/Pos                 Neg                    Intimal thickening
  **4 (Dys)**    Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **5 (Dys)**    Neg                 Neg                             Neg             Neg/Neg                 Neg                    Microhemorrhages
  **6 (Dys)**    Neg                 NFT and Th (sparse), tau-glia   Neg             Neg/Pos                 Neg                    Normal
  **7 (Dys)**    Neg                 NFT and Th (moderate)           Neg             Neg/Pos                 Neg                    Normal
  **8 (Dys)**    Neg                 Th (moderate)                   Pos (sparse)    Neg/Neg                 Neg                    Normal
  **9 (Dys)**    Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **10 (Dys)**   Neg                 NFT (rare)                      Pos (rare)      Neg/Pos                 Neg                    Normal
  **11 (Dys)**   Neg                 Th (sparse), pre-NFT (rare)     Pos (rare)      Neg/Neg                 Neg                    Normal
  **12 (Dys)**   Neg                 Neg                             Neg             Neg/Neg                 Neg                    Intimal thickening
  **13 (Dys)**   Neg                 Neg                             Neg             Neg/Pos                 Neg                    Intimal thickening
  **14 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **15 (C)**     Neg                 Th (sparse)                     Neg             Neg/Neg                 Neg                    Normal
  **16 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **17 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **18 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **19 (C)**     Neg                 Th (rare)                       Neg             Neg/Neg                 Neg                    Normal
  **20 (C)**     Neg                 NFT (rare)                      Neg             Neg/Neg                 Neg                    Hyperemia
  **21 (C)**     Neg                 Th (rare)                       Neg             Neg/Neg                 Neg                    Normal
  **22 (C)**     Neg                 Neg                             Neg             Neg/Pos                 Neg                    Normal
  **23 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Intimal thickening
  **24 (C)**     Neg                 Th (sparse)                     Neg             Neg/Neg                 Neg                    Normal
  **25 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal
  **26 (C)**     Neg                 Neg                             Neg             Neg/Neg                 Neg                    Normal

Abbreviations: C, Control; Dys, Dystonia; H&E, Hematoxylin and Eosin; Neg, Negative; NFT, Neurofibrillary Tangle; Pos, Positive; SN, Substantia Nigra; TDP43, TAR DNA-binding Protein 43; Th, Thread

Immunohistochemistry findings {#s3a}
-----------------------------

Overall, 5/13 Dys and 5/13 C were positive for tau lesions. In the majority of cases, tau lesions were sparse or rare (tau-NFT or tau-th), and only two Dys cases (cases \#7 and \#8) had moderate levels of tau lesions, mostly tau-th.

No C cases had *α*-synuclein-positive lesions (LBs or LNs), whereas three Dys cases (\#8, \#10, and \#11) did. These three cases were classified as possible Lewy Body disease (possLBD) of the brainstem.[@b40] None of the SN samples were positive for 1--42 *β*-amyloid (diffuse amyloid or neuritic plaques), ubiq, or pTDP43-positive cytoplasmic intraneuronal inclusions. Ubiq-positive intranuclear inclusions (Marinesco bodies \[MB\])[@b44] were observed in some cases, and more often in Dys than C. As a reminder, MB are eosinophilic intranuclear neuronal inclusions observed in human brains that have an uncertain origin and pathologic meaning. This intriguing finding has been reported previously; [@b30] however, larger studies are necessary to confirm the higher frequency of MB in Dys in general or in a specific Dys subtype. [Table 4](#t04){ref-type="table"} summarizes the immunohistochemistry findings in both groups.

Quantitative findings: neuronal counting {#s3b}
----------------------------------------

A total number of 496,601±130,010 and 648,926±162,475 pigmented neurons were estimated in the SNs of the Dys and C groups, respectively. The estimated nigral neuronal population in C did not differ proportionally from previous stereologic studies that assessed the entire SN length in control subjects.[@b45],[@b46]

Histograms depicting the estimated nigral pigmented neuronal counts and volumes are shown in **[Figure 2](#f02){ref-type="fig"}**. The estimated nigral pigmented neuronal population was calculated using neuronal numbers weighted for each section thickness per each subject. A significant reduction of pigmented neurons in SN of Dys versus C was found (*p* = 0.01). A separate computation after exclusion of all positive LB/LN and/or tau-NFT/th Dys (\#6, \#7, \#8, \#10, and \#11) and C (\#15, \#19, \#20, \#21, and \#24) cases was also performed. This second narrower computation confirmed a significant reduction of pigmented neurons in the SN of Dys (n = 8) versus C (n = 7) (*p* = 0.01). No significant differences in terms of neuronal counts were observed between childhood-onset Dys and adulthood-onset Dys cases regardless of whether cases with co-occurring nigral pathologies were excluded. [Table 5](#t05){ref-type="table"} summarizes all comparisons for neuronal counting between Dys and C with their numerical values and statistical significance. See also [Figure 4](#f03){ref-type="fig"}.

![**Histograms of the Estimated Mean Number of SN Pigmented Neurons in 13 Dys Patients and 13 C Subjects.** The histograms on the left side include all Dys and C brains, while those on the right show Dys and C data after exclusion of all brains with immunohistochemical evidence of co-occurring pathologies. The lower part of the figure shows histograms of cell body, nuclear, and nucleolar mean volumes of pigmented neurons in the SN. The y-axis indicates mean volumetric values expressed in µm^3^. \**p*\<0.01. Abbreviations: C, Control; Dys, Dystonia; SN, Substantia Nigra.](tre-05-301-6570-1-g002){#f02}

![**Co-occurring Pathologies in the SN of Dys Patients.** Abbreviations: CD, Cervical Dystonia (subject Dys\#6); Ch-on, Childhood-onset; Gen., Generalized (Subject Dys\#13); LB, *α*-synuclein-positive Lewy Body; MB, Marinesco Body (intranuclear eosinophilic body); Tau-NFT, Tau-positive Neurofibrillary Tangle; Tau-th, Tau-positive Thread; Ubiq+, Ubiquitin Positivity.](tre-05-301-6570-1-g003){#f03}

###### Estimated Number of Pigmented Neuron Population and their Cellular and Subcellular Volumes in the SN of Dys and C Subjects. The table shows the estimated number and cell body, nuclear, and nucleolar volumes of pigmented neurons (mean±SD) in the SN of Dys and C across all considered subtypes. The significance of *p*-values is indicated for each type of comparison. The significance was established when *p*\<0.01.

  Comparisons                                                       Estimated Number of Pigmented Neurons (±SD)                  Cell Body                                    Nuclear                                   Nucleolar
  ----------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------- ----------------------------------------- ----------------------------
  Dys (n = 13) vs. C (n = 13)                                       496,601.6±130,009.4 vs. 648,925.7±169,700.2 (*p* = 0.0186)   15,136.1±4,122.2 vs. 15,632.1±2,718.2 (ns)   1,768.1±505.4 vs. 1,662.2±347.0 (ns)      26.0±8.2 vs. 25.9±3.1 (ns)
  \*Dys (n = 8) vs. \*C (n = 8)                                     518,991.3± 139,210.6 vs. 725,432.2±16,531.8 (*p* = 0.0045)   14,340.1±5,097.2 vs. 15,936.1±2,992.1 (ns)   1,627.1±560.1 vs. 1,767.2±399.2 (ns)      25.8±8.9 vs. 26.0±3.8 (ns)
  Adulthood-onset Dys (n = 3) vs. C (n = 13)                        408,748.1±85,747.9 vs. 648,925.7±169,700.2 (*p* = 0.0366)    13,669.1±3,557.2 vs. 15,936.1±2,992.1 (ns)   1,661.1±491.9 vs. 1,662.2±347.0 (ns)      24.0±6.8 vs. 25.9±3.1 (ns)
  \*Adulthood-onset Dys (n = 2) vs. \*C (n = 8)                     408,748.1±85,747.9 vs. 725,432.2±16,531.8 (*p* = 0.0366)     11,709.5±1,510.5 vs. 15,222.7±766.4 (ns)     1,491.1±556.6 vs. 1,796.1±372.0 (ns)      24.1±9.7 vs. 26.0±5.2 (ns)
  Childhood-onset Dys (n = 10) vs. C (n = 13)                       503,648.9±124,734.1 vs. 648,925.7±169,700.2 (*p* = 0.0436)   15,764.1±4,569.2 vs. 15,632.1±2,718.2 (ns)   1,764±533.1 vs. 1,662±347.0 (ns)          27.1±9.1 vs. 25.9±3.1(ns)
  \*Childhood-onset Dys (n = 6) vs. \*C (n = 8)                     541,369.8±112,651.7 vs. 725,432.2±16,531.8 (*p* = 0.0192)    15,216.7±1,373.2 vs. 15,222.7±766.4 (ns)     1,671.7±400.9 vs. 1,796.1±372.0 (ns)      25.6±5.2 vs. 26.0±5.2 (ns)
  Childhood-onset Dys (n = 10) vs. Adulthood-onset Dys (n = 3)      504,647.0±371,697.8 vs. 463,247.9±97,180.9 (ns)              15,764.1±4,569.2 vs. 13,669.1±3,557.2 (ns)   1,764±533.1 vs. 1,662.2±347.0 (ns)        27.1±9.1 vs. 25.9±3.1 (ns)
  \*Childhood-onset Dys (n = 6) vs. \*Adulthood-onset Dys (n = 2)   535,589.0±371,697.8 vs. 512,103.1±67,582.0 (ns)              15,216.7±1,373.2 vs. 11,709.5±1,510.5 (ns)   1,671.7±400.9 vs. 1,796.1±372.0 (ns)      25.6±5.2 vs. 26.0±5.2 (ns)
  Generalized Dys (n = 6) vs. segmental/focal Dys (n = 7)           514,023.1±98,491.31 vs. 481,668.9± 163,184.3 (ns)            14,379.1±1,004.9 vs. 15,784.8±3,587.4 (ns)   1,767.6±409.5 vs. 15,784.8±3,587.4 (ns)   28.9±3.5 vs. 23.4±4.2 (ns)
  \*Generalized Dys (n = 5) vs. \*segmental/focal Dys (n = 3)       513,204.1±139,210.5 vs. 528,636.7±139,513.19 (ns)            13,984.5±1,373.2 vs. 14,932.3±5,683.2 (ns)   1,655.5±400.9 vs. 1,982.4±312.7 (ns)      27.2±1.0 vs. 32.1±5.5 (ns)

Abbreviations: C, Control; Dys, Dystonia; ns, not significant; SD, Standard Deviations; SN, Substantia Nigra.

The mean for each type of volumetric measurement (cell body, nucleus, and nucleolus) performed on nigral pigmented neurons of Dys and C are shown in [Table 5](#t05){ref-type="table"}. A mean of 179.7±56.3 nigral pigmented neurons were volumetrically measured (range: 97--297) across all cases. No difference was measured between the mean numbers of pigmented neurons volumetrically measured in Dys (157.5±40.0) and C (201.9±56.3). Importantly, no significant differences in mean cellular, nuclear, or nucleolar volumes were found across all types of comparisons between the Dys and C groups ([Table 5](#t05){ref-type="table"}). [Table 6](#t06){ref-type="table"} shows the coefficient error (CE) values for each performed measurement (counting and volumes) for each subject in the study.

Table 6Estimated Number of Nigral Pigmented Neuronal Populations and Volumetric Measurements with Corresponding Values of Gunderson\'s Coefficient Errors in the Dys and C Groups. The table shows single values obtained in each Dys and C subject in terms of estimated number of pigmented nigral neurons counted. Each mean neuronal counting estimation has a corresponding mean cell body, nuclear, and nucleolar volume for all examined subjects. CE is an indicator of precision for the performed estimations and is generally acceptable if \<0.10.**Subject\#Mean Pigmented Neuronal CountCEMean Cellular VolumeCEMean Nuclear VolumeCEMean Nucleolar VolumeCE1 (Dys)**530,990.70.0518,457.90.0062,332.30.00638.10.007**2 (Dys)**409,690.00.0712,777.60.0031,884.70.00331.00.004**3 (Dys)**494,021.30.0610,641.40.0051,097.50.00617.20.022**4 (Dys)**604,631.90.0612,589.70.0041,730.00.00527.30.005**5 (Dys)**682,198.80.0521,377.80.0051,752.90.00524.40.006**6 (Dys)**491,138.20.0517,297.20.0071,510.40.00724.80.006**7 (Dys)**275,364.90.0816,926.60.0091,840.50.00921.60.011**8 (Dys)**322,533.20.0717,586.40.0072,002.10.00723.70.062**9 (Dys)**405,516.60.065,273.80.006581.80.0098.00.008**10 (Dys)**696,735.90.0513,886.40.0042,286.80.00521.30.049**11 (Dys)**518,118.10.0616,352.00.0062,328.50.00737.40.007**12 (Dys)**414,003.90.0617,771.60.0061,533.10.00630.60.079**13 (Dys)**610,877.40.0515,829.50.0052,100.20.00532.00.005**14 (C)**787,705.80.0613,858.90.0041,115.20.00522.00.016**15 (C)**648,925.70.0611,253.30.0071,390.60.00823.60.045**16 (C)**351,255.90.0515,631.90.0031,663.00.00325.80.004**17 (C)**856,559.10.0611,864.00.0031,600.50.00324.00.004**18 (C)**621,172.80.0715,532.50.0072,084.90.00829.00.053**19 (C)**370,591.10.0620,711.70.0101,585.10.00921.10.010**20 (C)**571,960.50.0618,168.90.0031,704.50.00427.30.048**21 (C)**696,553.00.0615,519.30.0031,365.80.00326.80.034**22 (C)**488,401.40.0514,754.40.0041,327.20.00525.10.057**23 (C)**800,241.80.0518,947.80.0041,660.00.00428.40.004**24 (C)**718,722.80.0415,375.80.0042,007.70.00329.70.004**25 (C)**750,282.50.0516,342.60.0041,788.90.00523.00.059**26 (C)**773,662.10.0515,258.70.0032,315.10.00330.50.004[^3]

Discussion {#s4}
==========

To our knowledge, this is the first investigation to apply rigorous neuropathologic quantitative methods to estimate the numbers and volumes of nigral pigmented neurons in a consistent series of Dys and an equivalent number of age-matched control brains that were systematically assessed by specific immunohistochemistry protocols for the individuation and exclusion of possible co-occurring pathologies affecting the SN. Importantly, this is the largest quantitative analyses of Dys brain tissue to date. Our results show that both adulthood- and childhood-onset Dys patients exhibited significant reductions of pigmented SN neurons compared to the C groups. Furthermore, these quantitative analyses showed no significant differences between Dys and C in terms of nigral pigmented neuronal volumes. These findings would seem to exclude phenomena of atrophy or hypertrophy for this type of pigmented neuron in non-DYT1 idiopathic Dys brains. Previous studies describing semiquantitative or pathologic findings on Dys brains mainly focused on genetic Dys, specifically DYT1 cases.[@b20],[@b29] Therefore, most of the findings from those studies do not seem to be directly applicable to the Dys cohort examined here.

The previous report of larger pigmented neurons in the SN of subjects with Dys (with and without GAG deletions)[@b29] was not confirmed in our non-DYT1 idiopathic Dys cohort. However, our findings do not exclude the possibility that certain genetic forms of Dys, such as DYT1 characterized by TorsinA protein dysfunction, could induce specific cellular adaptation phenomena during brain development. Indeed, it could be hypothesized that congenital reductions or enlargements of specific neuronal types are present in some specific sensory-motor cortical or subcortical areas[@b47] as adaptive or compensatory neuronal mechanisms against the subjacent initial pathology. Phenomena of neuroplasticity[@b48] in Dys patients illustrated by some recent functional neuroimaging studies[@b49] might support a neurodevelopmental hypothesis of idiopathic Dys.

Limitations and strengths {#s4a}
-------------------------

Although the quantitative methods used in this study were very similar to those used in unbiased stereology investigations, and we tried to minimize confounding factors, it is important to consider our results in the context of some important limitations:

1.  The obtained quantitative estimations were not based on the entire length of the SN. Although we used well-established and reliable stereology tools (such as the Optical Fractionator and Nucleator probe) and precise histological, neuropathologic, and clinical approaches (i.e., serial sectioning, anatomical randomization, exclusion of co-occurring pathologies, same mean age at death, etc.), this investigation cannot be defined as an unbiased stereology study mainly due to the impossibility of obtaining the entire structure of interest (SN). Our preliminary novel findings need to be confirmed by unbiased stereological investigations that include the entire anatomical extension of SN.

2.  We assessed a low number of cases for each specific type of Dys. It is highly probable that different types of Dys have different causes and unique pathologic features. For example, it is highly probable that adulthood- and childhood-onset forms of Dys represent two different pathogenetic pathways. However, it cannot be totally excluded that they share some common clinical and pathologic features. Then, we cannot be certain that future larger neuropathologic quantitative stereologic studies focusing on a single type of Dys could confirm our findings only on some specific type or group of Dys.

This investigation, however, also has several strengths:

1.  To the best of our knowledge, this is the first clinicopathologic correlative study performed on a relatively large number of autopsy-Dys brains (n = 13) and an equivalent amount of autopsy-confirmed age-matched control brains applying rigorous neuropathologic quantitative methods to describe possible specific characteristics (e.g., a reduced number of pigmented neurons in the SN).

2.  Extensive histopathologic analyses were performed on each single Dys and C case, including possible co-occurring pathologies affecting the SN. In our opinion, this type of immunohistochemistry assessment is essential to decrease the possibility that a lower number of nigral pigmented neurons could be due to the simultaneous presence of nigral degenerative pathologies. These could indeed represent important confounders that are not directly or necessarily related to the pathogenesis of idiopathic forms of Dys. However, our findings do not exclude the possibility that nigral or extranigral neurodegenerative phenomena (e.g., during aging), could contribute to the progression or initial disease manifestations.

3.  There was a remarkable effort in reclassifying most of the non-DYT1 Dys autopsy cases available at UMBTB following the most recent classification system changes.[@b04] The reclassification was based on the careful re-examination of all available medical records. This effort was an important attempt to describe new neuropathologic findings using precious brain tissues previously donated and already available to the scientific community in consideration of newer clinical views and modern neuropathologic quantitative and immunohistochemistry techniques.

Our neuropathologic morphometric-quantitative findings, which are similar to the results of other recent pathologic studies,[@b31],[@b32] seem to confirm the direct involvement of the SN in the pathomechanisms of Dys. Importantly, the involvement of the SN in Dys with regard to a reduced number of pigmented neurons (mainly dopaminergic cells) is not necessarily or directly related to dopaminergic dysfunction *per se* (i.e., dopaminergic function loss), or to a specific clinical phenomenology of Dys. In fact, in a hypothetical and more global context of a neurodevelopmental disorder, it is possible that other nondopaminergic circuits and neurotrasmettitorial abnormalities (i.e., gamma-aminobutyric acid, acetylcholine)[@b50],[@b51] could play important or even major roles. Moreover, results from two clinical and functional neuroimaging series[@b52],[@b53] support a more global view on Dys phenomenology where the motor and nonmotor abnormalities observed in Dys patients are associated with a broad spectrum of abnormalities in multiple cerebral regions, some of which are nondopaminergic. Furthermore, at a higher speculative level, a neurodevelopmental hypothesis for idiopathic Dys (or some specific form of it) that would not primarily involve dopaminergic dysfunction (i.e., dopaminergic function loss) could help to explain the constant and frustrating inefficacy of dopaminergic therapies in most Dys patients, with the remarkable exception of DRD.

Larger studies are needed to confirm our novel findings on idiopathic Dys. However, these preliminary results seem to suggest the presence of a specific neuropathologic substrate in idiopathic Dys in the form of a reduced number of nigral pigmented neurons that is not due to a neurodegenerative process.

Some very important questions remain:

1.  In Dys brains, is the nigral pigmented neuronal reduction a loss of neurons (neurodegenerative hypothesis), or does it represent, as we hypothesize, a possible neurodevelopmental defect (neurodevelopmental hypothesis)?[@b54] In support of the latter hypothesis is the observation that volumetric measurements of nigral pigmented neurons in Dys cases were not significantly different from those in C brains as would be expected if atrophic-neurodegenerative processes were actually involved. These morphometric findings are especially relevant considering that the reduction of nigral pigmented neurons in Dys versus C remained significant even after immunohistochemical exclusion of some copathologies frequently associated with SN neuronal degeneration.

In addition, the absence of a difference in the number of nigral pigmented neurons between the only available posttraumatic dystonia case (\#10) and C brains seems to support a neurodevelopmental hypothesis for idiopathic Dys. In the future, larger studies of posttraumatic and nonposttraumatic/idiopathic Dys could provide pathologic findings that support or exclude a neurodevelopmental defect of the SN in idiopathic Dys.

1.  Does the nigral pigmented neuronal reduction primarily or exclusively affect dopaminergic neurons? Does it specifically impact the pars compacta or pars reticulata of the SN? It is important to recall that the SN (and basal ganglia \[BG\] in general) contains a considerable level of somatotopic neuronal organization and neurotrasmettitorial complexity. It is not possible to exclude then that fewer nigral pigmented neurons could mainly affect specific subregions of the SN, thus influencing specific cellular and pathogenetic mechanisms and causing various clinical phenotypes and motor and nonmotor manifestations of Dys.

2.  Does the nigral neuronal reduction (or loss) represent a cause or an effect of other pathologic (or neurodevelopmental) phenomena?

Our preliminary quantitative findings, if confirmed, would offer novel insight into specific neuronal alterations in idiopathic Dys. However, these new findings need to take into account very complex pathophysiologic mechanisms and possible pathologic differences across the various forms of Dys.[@b55]--[@b58] Nonetheless, partial overlapping or common mechanisms among groups or subgroups of Dys with similar clinical phenotypes remain possible.[@b59]

Future major efforts should include unbiased stereological analyses in larger groups of different genetic and nongenetic forms of Dys to confirm our observation of fewer pigmented neurons in the SN, and if so, clarify whether this decrease is "congenital" or neurodegenerative in nature. Another important issue is whether this cellular abnormality is unique to the SN or specific forms of Dys.

![**Histograms of Estimated Mean Numbers of Pigmented Neurons.** We quantified neurons in the substantia nigra (SN) of dystonia (Dys) vs. age-matched control subjects (C) and compared counts in types of dystonia (adulthood-onset, childhood-onset, generalized, focal/segmental \[foc/seg\] dystonias). For each measurement there are two histograms showing the obtained estimated number of neurons before and after exclusion of all nigral co-occurring pathologies (*β*-amyloid, tau, Lewy bodies, and ubiquitin). All co-occurring nigral pathologies were assessed using immunohistochemistry protocols.](tre-05-301-6570-1-g004){#f04}
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